Immunitybio Non Current Assets Total from 2010 to 2024
IBRX Stock | USD 5.27 0.36 7.33% |
Non Current Assets Total | First Reported 2014-12-31 | Previous Quarter 217.3 M | Current Value 210.4 M | Quarterly Volatility 60.7 M |
Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.2 M, Interest Expense of 135.7 M or Selling General Administrative of 91.7 M, as well as many exotic indicators such as Price To Sales Ratio of 3.9 K, Dividend Yield of 3.0E-4 or Days Sales Outstanding of 1.8 K. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
Immunitybio | Non Current Assets Total |
Latest Immunitybio's Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of Immunitybio over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Immunitybio's Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.
Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
Timeline |
Immunitybio Non Current Assets Total Regression Statistics
Arithmetic Mean | 85,228,893 | |
Geometric Mean | 25,677,749 | |
Coefficient Of Variation | 86.29 | |
Mean Deviation | 58,147,915 | |
Median | 93,178,000 | |
Standard Deviation | 73,542,966 | |
Sample Variance | 5408.6T | |
Range | 220.7M | |
R-Value | 0.88 | |
Mean Square Error | 1346T | |
R-Squared | 0.77 | |
Significance | 0.000018 | |
Slope | 14,419,949 | |
Total Sum of Squares | 75719.9T |
Immunitybio Non Current Assets Total History
About Immunitybio Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Immunitybio income statement, its balance sheet, and the statement of cash flows. Immunitybio investors use historical funamental indicators, such as Immunitybio's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Immunitybio investors may use each financial statement separately, they are all related. The changes in Immunitybio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunitybio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immunitybio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Non Current Assets Total | 210.4 M | 115.9 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Immunitybio Correlation against competitors. For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Immunitybio Stock analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Immunitybio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunitybio. If investors know Immunitybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunitybio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.15) | Revenue Per Share 0.001 | Quarterly Revenue Growth 0.904 | Return On Assets (0.52) |
The market value of Immunitybio is measured differently than its book value, which is the value of Immunitybio that is recorded on the company's balance sheet. Investors also form their own opinion of Immunitybio's value that differs from its market value or its book value, called intrinsic value, which is Immunitybio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunitybio's market value can be influenced by many factors that don't directly affect Immunitybio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunitybio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunitybio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunitybio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.